Trials / Completed
CompletedNCT01248429
Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases
National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 154 (actual)
- Sponsor
- Centre Oscar Lambret · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study describes the elevation of CPK in patient treated for solid tumors by TKI
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CPK dosage | CPK dosage during a blood sample realized at least one week after the begining of the treatment |
| OTHER | Clinical exam | Examination of the patient for myalgia, cramps, medical history and concomitant medication |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2010-12-01
- Completion
- 2013-01-15
- First posted
- 2010-11-25
- Last updated
- 2026-03-16
Locations
27 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01248429. Inclusion in this directory is not an endorsement.